Assessing the Efficacy and Safety of the Allurion® Gastric Balloon in Latin American Patients: A Multicenter Case Series

Introduction Allurion® gastric balloon (AGB) is an innovative option for treating overweight and grade I obesity or as a bridging treatment for bariatric surgery or because the patient does not desire a surgical intervention. This study aimed to evaluate the efficacy and safety of the AGB in a multicentric cohort. Materials and methods A retrospective analysis of consecutive cases treated with AGB (≥18 years old with BMI ≥27) was performed in eight centers in 3 countries in Latin America (Argentina, Chile, and Peru), between September 2021 to September 2022, with a 12-month follow-up. Results 402 patients were included (median BMI of 32.81 kg/m ² ). Mean TWL% was 8.3%, 11.6%, and 14.9% at 3, 6, and 12 months respectively, with a follow-up of 93.03%, 75.37% and 40.54%. The adverse event rate was 1.24% (n=5). During the first 7 days, 34.58% (n=139) experienced concomitant symptoms, and 1.99% (n=8) asked for endoscopic balloon extraction because of intolerance. The complication rate was 6.46% (n=26). Readmission index was 4.97% (n=20) and reintervention was 2.23% (n=9). Balloon elimination was experienced by 5.7% of patients in the first 14 days, 29.10% (n=117) before the 3rd month, and 62.68% (n=252) after the 16th week. Early deflation rate was 2.73% (n=11). Digestive track elimination was perceived by 26.61%. Conclusions AGB is a safe and effective option for the treatment of overweight and obesity in Latin America. Lifestyle changes and continuous support with a multidisciplinary team are essential to achieving good mid- to long-term outcomes.